At the time I am writing this, I am only seeing compounded semaglutide as an option, no tirzepatide, which can be a bummer as tirzepatide tends to be more effective (but also usually costs ~$100 more per month)
Advanced molecular imaging in large-vessel vasculitis: adopting FDG-PET into a clinical workflow
This personalization ensures patients invest in the medication most likely to deliver results, reducing the risk of costly treatment failures
GLP-1 medications stabilize blood sugar levels and improve insulin sensitivity, helping reduce the risk of diabetes-related heart complications
I chose the $297 plan and waited for my final approval
Or will high costs, insurance restrictions, side effect burdens, and supply constraints limit them to a small fraction of eligible patients